Scarica l'app Stockscreener
4.45
0.00%
0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ATRA Giù?
Forum
Previsione
Atara Biotherapeutics Inc Borsa (ATRA) Ultime notizie
What are analysts’ price targets for Atara Biotherapeutics Inc.2025 Risk Factors & Real-Time Volume Spike Alerts - mfd.ru
Will Atara Biotherapeutics Inc. stock recover faster than peersJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - mfd.ru
Is Atara Biotherapeutics Inc. stock ready for breakout2025 Trading Recap & Long-Term Capital Growth Strategies - mfd.ru
Can Atara Biotherapeutics Inc. stock double in the next yearTrend Reversal & Community Consensus Trade Alerts - mfd.ru
How Atara Biotherapeutics Inc. stock reacts to job market dataMarket Trend Report & Technical Pattern Based Signals - mfd.ru
Nasdaq Moves: Will Atara Biotherapeutics Inc benefit from green energy policiesLayoff News & Community Supported Trade Ideas - baoquankhu1.vn
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - Chartmill
Highs Report: What analysts say about Atara Biotherapeutics Inc stockMarket Weekly Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
Fundamentals Check: Does Nuveen Churchill Direct Lending Corp have pricing powerJuly 2025 WrapUp & Weekly High Momentum Picks - baoquankhu1.vn
Can Atara Biotherapeutics Inc stock double in the next yearMarket Activity Report & Accurate Intraday Trade Tips - baoquankhu1.vn
Is Atara Biotherapeutics Inc. stock influenced by commodity pricesJuly 2025 Recap & Reliable Breakout Stock Forecasts - mfd.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - Chartmill
Once a Ventura County biotech heavyweight, Atara fights for its life - Ventura County Star
Price-Driven Insight from (ATRA) for Rule-Based Strategy - Stock Traders Daily
Short Squeeze: Can Atara Biotherapeutics Inc weather a recessionJuly 2025 WrapUp & Low Drawdown Trading Techniques - baoquankhu1.vn
Patterns Watch: Can Atara Biotherapeutics Inc weather a recessionMarket Sentiment Summary & Reliable Price Breakout Signals - baoquankhu1.vn
Pancreatic Cancer Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dragonfly Therapeutics, Keymed B, Tango Therapeutics, Atara Biotherapeutics, Keymed Biosciences Co. Ltd - Barchart.com
Tabelecleucel’s Phase 3 EBV+ PTLD Trial Progress Signals Continued Potential for Atara Biotherapeutics - TipRanks
FinancialContentINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - FinancialContent
What momentum indicators show for Atara Biotherapeutics Inc. stockMarket Rumors and News & Trusted Financial Advisors at No Cost - bollywoodhelpline.com
FDA Again Rejects Atara - labusinessjournal.com
Analyst Calls: Can Ligand Pharmaceuticals Incorporated beat the S P 5002025 Price Momentum & Trade Opportunity Analysis - baoquankhu1.vn
Aug Summary: Will HAFN benefit from green energy policiesStock Surge & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Innovation Ltd Panacea Sells 80,554 Shares of Atara Biotherapeutics (NASDAQ:ATRA) Stock - Defense World
(ATRA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Atara Bio director Huang James sells $489k in shares By Investing.com - Investing.com Australia
Atara Bio director Huang James sells $489k in shares - Investing.com
Aug Selloffs: Is Atara Biotherapeutics Inc being accumulated by smart moneyTrade Exit Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel - FinancialContent
Entry Recap: Is Atara Biotherapeutics Inc stock dividend yield sustainableJuly 2025 Retail & Daily Profit Maximizing Tips - Bộ Nội Vụ
Canaccord Genuity Downgrades Atara Biotherapeutics (ATRA) to Hol - GuruFocus
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier) - TipRanks
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Atara receives FDA complete response letter for Ebvallo BLA application - Pharmaceutical Business review -
FDA rejects Atara’s tabelecleucel application in surprise reversal By Investing.com - Investing.com Nigeria
Canaccord Genuity Downgrades Atara Biotherapeutics to Hold From Buy, Adjusts PT to $6 From $25 - marketscreener.com
Atara Biotherapeutics' EBVALLO BLA Rejected by FDA, Stock Plummets 57% - Intellectia AI
Atara Biotherapeutics Stock Falls After FDA CRL On EBVALLO BLA - RTTNews
ATRA stock nearly halves in value after FDA refuses approval for immunotherapy: Retail sees 'big fight back' - MSN
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain - TipRanks
FDA rejects Atara’s tabelecleucel application in surprise reversal - Investing.com
Atara Biotherapeutics (ATRA) Shares Plunge After FDA Setback - GuruFocus
Atara plummets on FDA Complete Response Letter for tabelecleucel - Seeking Alpha
ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’ - Stocktwits
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
FDA Hits Atara Biotherapeutics’ T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD With Second CRL - CGTLive®
Atara, Pierre Fabre allege FDA about-face as agency hands down 2nd Ebvallo snub - Fierce Pharma
Why Is Atara Biotherapeutics Stock Sinking Monday?Atara Biotherapeutics (NASDAQ:ATRA) - Benzinga
US FDA declines to approve Atara's therapy for rare blood cancer - Reuters
Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next - TechStock²
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):